Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADVM-022 · 2 trials · 2 indications
BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS)
| Arm | Type | Description |
|---|---|---|
| Dose 1 | EXPERIMENTAL | A single intravitreal injection of ADVM-022 2E11 vg/eye |
| Dose 2 | EXPERIMENTAL | A single intravitreal injection of ADVM-022 6E10 vg/eye |
| Name | Type | Description |
|---|---|---|
| ADVM-022 | GENETIC | A single IVT injection of 2E11 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens |
Inclusion Criteria: * Male or female participants, ≥ 50 years of age * Willing and able to provide written, signed informed consent for this study * Demonstrated a meaningful response to anti-VEGF therapy * Participants must be under active anti-VEGF treatment for wet AMD and received a minimum of ...
ADVM-022 is an investigational gene therapy being developed for neovascular age-related macular degeneration (wet AMD). It is designed to deliver a gene that produces aflibercept, a protein that blocks vascular endothelial growth factor, to treat the condition. The therapy is administered via intravitreal injection.
ADVM-022 targets aflibercept, a protein that inhibits vascular endothelial growth factor. By delivering the gene for aflibercept, the therapy aims to enable sustained production of the protein within the eye, potentially reducing the need for frequent anti-VEGF injections in patients with wet age-related macular degeneration.
ADVM-022 is being developed by Adverum Biotechnologies, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol ADVM. The company is focused on gene therapies for ocular diseases.
ADVM-022 is currently in Phase 2 clinical development. It has completed a Phase 1 trial and is being evaluated in an active Phase 2 study. The drug is investigational and has not been approved by regulatory authorities.
ADVM-022 has been studied in two clinical trials. The Phase 1 trial (NCT03748784) was completed in the United States with 30 participants. The Phase 2 trial (NCT05536973), called LUNA, is active but not recruiting, with 69 participants in the United States, France, and the United Kingdom.
ADVM-022 is not the same as aflibercept. ADVM-022 is a gene therapy that delivers the gene for aflibercept, a protein that blocks vascular endothelial growth factor. The therapy is designed to produce aflibercept within the eye, whereas aflibercept itself is an approved anti-VEGF medication.